FONT-SIZE Plus   Neg

Shell Spots Sheen In Gulf Of Mexico; Shares Fall

Shares of European oil giant Royal Dutch Shell Plc (RDS-A, RDSA.L, RDSB.L, RDS-B) are falling over 5 percent in London after the company spotted a light sheen in the central portion of the Gulf of Mexico, between the Mars and Ursa production area. Shell has notified the National Response Center about the sheen.

The company said it currently has no indication that the sheen originates from wells in the Mars or Ursa projects.

Shell said that out of prudent caution it has activated the Louisiana Responder, a Marine Spill Response Corporation vessel.

The Louisiana Responder is an oil spill response vessel with skimming and boom capabilities. Shell has also requested flights to monitor the one by ten-mile sheen closely with additional aerial surveillance.

"At this time, the source of this sheen is unknown, and Shell's priority is to respond proactively, safely, and in close coordination with regulatory agencies. Updates will be provided as further action is taken," the company said..

RDSA.L is currently trading at 2,033 pence, down 108 pence or 5.04 percent, on a volume of 3.91 million shares.

RDS-A, which closed at $67.75, is falling close to 4 percent in pre-market trading.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Visa Inc. (V) on Monday reported an increase in profit for the fourth quarter, as revenues jumped driven largely by increase in customer spending and inclusion of Europe business. Earnings and revenues trumped Wall Street expectations. Foster City, California-based Visa's fourth-quarter profit rose... As Sony Corp. prepares to launch the new PlayStation 4 Pro gaming console on November 10, several new games that are compatible with the console have also been confirmed for launch. Game developers are readying to provide PlayStation 4 Pro support for many games on PS4. Shares of Advaxis Inc. dropped more than 13 percent in pre-market activity before paring losses to just more than 5 percent after the company said that it was not able to complete the second stage of the Phase 2 GOG-0265 trial as designed due to a clinical hold that affected its clinical development programs last year.
comments powered by Disqus
Follow RTT